Searchable abstracts of presentations at key conferences in endocrinology

ea0029p785 | Endocrine tumours and neoplasia | ICEECE2012

Mitochondrial respiratory chain defects: a novel molecular mechanism of Mitotane for treatment of Adrenocortical Carcinoma

Hescot S. , Slama A. , Paci A. , Remy H. , Chadarevian R. , Trabado S. , Lombes A. , Young J. , Baudin E. , Lombes M.

Mitotane (o,p’DDD) represents the most effective treatment of adrenocortical carcinoma (ACC). However, molecular mechanisms of mitotane action remain poorly understood. Mitochondrial (mt) impact of mitotane has previously been suggested but not yet fully validated. We investigated functional consequences of mitotane exposure on mitochondrial steroidogenesis, respiratory chain activity and biogenesis, using human adrenocortical secreting H295R and non-secreting SW13 cells....

ea0026p72 | Endocrine tumours and neoplasia | ECE2011

Distribution of mitotane and its two metabolites in liproprotein fractions of patients with adrenocortical carcinoma

Cazaubon Y , Broutin S , Seck A , Remy H , Lemare F , Bidart J M , Chougnet C , Leboulleux S , Schlumberger M , Baudin E , Paci A

Introduction: Adrenocortical carcinoma (ACC) is a rare tumor of the adrenals with poor prognosis (survival rate for metastatic patients <15% at 5 years). Mitotane (o,p′-DDD) is the main therapeutic option with up to 66% objective response rates in patients with serum levels between 14 and 20 mg/l. Its two main metabolites are o,p′-DDA and o,p′-DDE which plasma levels are not correlated to therapeutic response. Mitotane is a lipophilic drug that accumulate...